Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.
An antibody-drug conjugate significantly extends survival for endometrial cancer patients who've already exhausted chemotherapy and immunotherapy.
This study aimed to compare sac-TMT with the treatment of physician's choice (TPC) in patients with endometrial cancer who had been previously treated with platinum-based chemotherapy and immunotherapy. Sac-TMT significantly improved progression-free survival and overall survival versus TPC in patients with advanced or recurrent endometrial cancer previously treated with platinum-based chemotherapy and immunotherapy.
What the study was
- Study design
- Randomized controlled trial
- Sample size
- 390
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Lancet
Why it surfaced
Randomized controlled trial; human evidence; PubMed abstract reviewed; conservative rubric score 8/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.